NCT06980350 2025-07-29
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Sun Yat-sen University
Completed
Clinical Trials
14 trialsNCT07036016 2025-06-25
Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Completed
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed
NCT03868046 2025-04-01
AUTENTIC
Hospital Universitario Araba
Completed
NCT06900686 2025-03-28
Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival
Sun Yat-sen University
Completed
NCT05934214 2024-03-05
EXIT
Groupe Hospitalier Pitie-Salpetriere
Completed
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT06011330 2023-08-30
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT05942768 2023-07-12
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT05535998 2022-09-10
TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Completed
NCT05307926 2022-09-07
Postoperative Adjuvant Therapy of HCC Based on PD-1
Tongji Hospital
Completed
NCT05489692 2022-08-10
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Completed
NCT05326906 2022-05-16
The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis
Hunan Province Tumor Hospital
Completed
NCT03492242 2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed